XL880

XL880 (also known as Foretinib) is an experimental drug candidate in the class of kinase inhibitors. It was developed by Exelixis and is currently being evaluated in clinical trials for its potential use in the treatment of various types of cancer.

Mechanism of Action[edit | edit source]

XL880 works by inhibiting the activity of certain protein kinases, which are enzymes that modify other proteins by chemically adding phosphate groups to them. Specifically, XL880 targets the MET and VEGFR2 kinases, which are often overactive in cancer cells. By blocking these kinases, XL880 can potentially slow down or stop the growth of cancer cells.

Clinical Trials[edit | edit source]

XL880 has been tested in several clinical trials for its potential use in treating different types of cancer. These trials have evaluated the drug's safety, efficacy, and optimal dosing regimen. The results of these trials have been mixed, with some showing promise and others showing limited effectiveness.

Side Effects[edit | edit source]

Like all drugs, XL880 can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and diarrhea. More serious side effects, such as liver damage and heart problems, have also been reported.

Future Directions[edit | edit source]

Research on XL880 is ongoing, with several clinical trials currently in progress. These trials aim to further evaluate the drug's safety and efficacy, as well as to determine the best way to use it in combination with other treatments.

See Also[edit | edit source]

XL880 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.